SCREENING AND MONITORING FOR BLADDER CANCER: REFINING THE USE OF NMP22
Authors:
- 1 July 2001
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 166 (1) , 75-78
Abstract
Conclusions Awareness and exclusion of the categories of false-positive results can increase the specificity and positive predictive value of NMP22, enhancing the clinical use of this urinary tumor marker.Keywords
This publication has 16 references indexed in Scilit:
- Predicting Cancer Progression in Patients With Stage T1 Bladder CarcinomaJournal of Clinical Oncology, 1999
- IMMUNOCYT 1 : A NEW TOOL FOR DETECTING TRANSITIONAL CELL CANCER OF THE URINARY TRACTJournal of Urology, 1999
- EDITORIAL: DO WE HAVE A PROSTATE SPECIFIC ANTIGEN FOR BLADDER CANCER?Journal of Urology, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- CAN URINE BOUND DIAGNOSTIC TESTS REPLACE CYSTOSCOPY IN THE MANAGEMENT OF BLADDER CANCER?Journal of Urology, 1998
- Improved detection of recurrent bladder cancer using the bard bta stat testUrology, 1997
- Detection of bladder cancer recurrence by microsatellite analysis of urineNature Medicine, 1997
- Molecular Detection of Primary Bladder Cancer by Microsatellite AnalysisScience, 1996
- Radical Cystectomy for Stages TA, TIS and T1 Transitional Cell Carcinoma of the BladderJournal of Urology, 1994
- Multivariate Analysis of Progression in Superficial Bladder CancerBritish Journal of Urology, 1993